<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Phys Ther Sci</journal-id><journal-id journal-id-type="iso-abbrev">J Phys Ther Sci</journal-id><journal-id journal-id-type="publisher-id">JPTS</journal-id><journal-title-group><journal-title>Journal of Physical Therapy Science</journal-title></journal-title-group><issn pub-type="ppub">0915-5287</issn><issn pub-type="epub">2187-5626</issn><publisher><publisher-name>The Society of Physical Therapy Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">jpts-2014-234</article-id><article-id pub-id-type="doi">10.1589/jpts.26.1825</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effect of Aerobic Exercise on Risk Factors of Cardiovascular Disease and the
Apolipoprotein B / Apolipoprotein A-1 Ratio in Obese Woman</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Dae-Young</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Jung</surname><given-names>Sun-Young</given-names></name><degrees>PhD, PT</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref rid="cor1" ref-type="corresp"><sup>*</sup></xref></contrib><aff id="aff1"><label>1)</label> Research Institute of Sports Medicine, Department of
Protection Science, Kyungwoon University, Republic of Korea</aff><aff id="aff2"><label>2)</label> Department of Physiology, College of Medicine, Kyung Hee
University: 1 Hoigi-dong, Dongdaemoon-gu, Seoul 130-701, Republic of Korea</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Corresponding author. Sun-Young Jung (E-mail: <email xlink:href="strongsun@hanmail.net">strongsun@hanmail.net</email>)</corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="ppub"><month>11</month><year>2014</year></pub-date><volume>26</volume><issue>11</issue><fpage>1825</fpage><lpage>1829</lpage><history><date date-type="received"><day>16</day><month>4</month><year>2014</year></date><date date-type="accepted"><day>21</day><month>5</month><year>2014</year></date></history><permissions><copyright-statement>2014&#x000a9;by the Society of Physical Therapy Science</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. </license-p></license></permissions><abstract><p>[Purpose] The objective of this study was to confirm whether consistent aerobic exercise
has an effect on the apolipoprotein B/apolipoprotein A-1 ratio or reduces the risk of
cardiovascular disease in obese women. [Subjects and Methods] The participants included 32
obese women between the ages of 40 and 49. Subjects were randomly divided into two groups
(n = 16 in each group): the control group and the exercise group. The exercise program in
this study corresponded to an intensity of 50 to 60% of the maximum volume of minute
oxygen consumption and was performed three times per week over 12 weeks. Physical
measurements, measurement of cardiorespiratory fitness and blood pressure, and blood
collection were done before and after the 12 weeks of exercise at the same time and under
the same conditions. [Results] Based on the results of this study, there were significant
interaction effects in both time and group weight, for body mass index, percent body fat,
maximum volume of minute oxygen consumption, high-density lipoprotein cholesterol, and the
apolipoprotein B/apolipoprotein A-1 ratio. Moreover, waist circumference, total
cholesterol, and the atherogenic index decreased significantly after 12 weeks of aerobic
exercise. [Conclusion] Regular aerobic exercise effectively improved cardiovascular risk
factors and decreased the obesity index in obese women.</p></abstract><kwd-group><title>Key words</title><kwd>Aerobic exercise</kwd><kwd>Apolipoprotein</kwd><kwd>Cardiovascular disease</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>INTRODUCTION</title><p>Obesity is increasing rapidly throughout the world and is a threatening public health
problem in many countries. The World Health Organization (WHO)<xref rid="r1" ref-type="bibr">1</xref><sup>)</sup> defines obesity as a disease that exerts a negative influence on
health and well-being through the accumulation of excess fat. Representative pathologies
accompanying obesity include cardiovascular disease (CVD), hypertension, hyperlipidemia,
diabetes, stroke, cancer, degenerative arthritis, and lung diseases including sleep apnea.
One of the first problems encountered in chronic disease of obese individuals is
hyperlipidemia, consisting of elevated blood cholesterol and triglyceride (TG) levels, the
most important independent risk factor of atherosclerosis and an important cause of coronary
artery disease (CAD)<xref rid="r2" ref-type="bibr">2</xref><sup>)</sup>. Research to date
points to high TG, total cholesterol (TC), low-density lipoprotein cholesterol (LDLC), and
high-density lipoprotein cholesterol (HDLC) as key risk factors for CAD<xref rid="r3" ref-type="bibr">3</xref><sup>)</sup>. However, after obtaining an enhanced understanding of
lipoprotein function and metabolism, rather than measuring traditional risk factors such as
TC, TG, HDLC, and LDLC, measuring apolipoprotein, apo- forming blood lipids, and lipoprotein
was recently deemed to be more predictive<xref rid="r3" ref-type="bibr">3</xref><sup>)</sup>. Apo is a key protein that forms many types of lipids and acts as a
coenzyme, either accelerating or suppressing functions related to transport and
re-distribution and metabolism of lipoproteins through the actions of tissue receptor
ligands<xref rid="r4" ref-type="bibr">4</xref><sup>)</sup>. Apo A is divided into the A I,
AII, and AIV types, which are important components of HDLC formation. Among these, apoA1 has
a static correlation with HDLC, and the expression level of apoA1 is determined by the HDLC
concentration. Moreover, it eliminates excess cholesterol in the body, converts cholesterol
to HDL, and activates lecithin cholesterol acyl transferase (LCAT), which is responsible for
reverse cholesterol transport (RCT) to the liver<xref rid="r3" ref-type="bibr">3</xref><sup>)</sup>. It is known that blood HDLC levels are inversely correlated with
CVD risk factors. According to related epidemiological studies, for every 1&#x02005;mg/dL increase
in HDLC, the risk for CAD is lowered by 2&#x02013;3%, and the risk of death is lowered by 6%<xref rid="r5" ref-type="bibr">5</xref><sup>)</sup>. HDLC undergoes a complex biosynthesis and
performs many widely known functions within the body, including diverse protective
mechanisms against atherosclerosis<xref rid="r6" ref-type="bibr">6</xref><sup>)</sup>. Blood
HDLC is composed of diverse types of lipoprotein based on the surface polarity, and apoA1 is
known to play the most pivotal role in the production and functioning of HDLC<xref rid="r6" ref-type="bibr">6</xref><sup>)</sup>. On the other hand, apoB particles
constituting LDL, intermediate-density lipoprotein (IDL), and very-low-density lipoprotein
(VLDL), combine the LDL particle with the LDL receptor, contributing to the absorption of
cellular cholesterol. Apolipoprotein B (apoB) anchors particles responsible for creating
atheroma in the arterial walls and pulls in complete lipoproteins, forming foam cells from
macrophages and the subendothelium<xref rid="r7" ref-type="bibr">7</xref><sup>)</sup>.
Therefore, high blood levels of ApoB are known as causal factors that increase the risk of
CAD<xref rid="r3" ref-type="bibr">3</xref><sup>)</sup>. Such a ratio between
apolipoprotein B and apolipoprotein A-1 (apoB/apoA1 ratio) forms a strong correlation with
metabolic syndrome and CVD<xref rid="r7" ref-type="bibr">7</xref>, <xref rid="r8" ref-type="bibr">8</xref><sup>)</sup>. Recently, blood apoB levels and apoA1 concentrations have
been suggested to have a strong impact on traditionally used LDLC and HDLC<xref rid="r9" ref-type="bibr">9</xref><sup>)</sup>. Moreover, the apoB/apoA1 ratio has an
independent correlation with atherosclerosis, and it has been reported that individuals with
high apoB/apoA1 ratios have greater metabolic risk factors<xref rid="r10" ref-type="bibr">10</xref><sup>)</sup>.</p><p>Methods of prevention and treatment of obesity and cardiovascular disease currently include
exercise, diet control, and pharmacotherapy. Among these, pharmacotherapy is less effective
and has multiple side effects, so it is not widely implemented, whereas diet control is
effective for weight loss but lowers the resting metabolic rate, which has the disadvantage
of decreasing both body fat and lean body weight.</p><p>Especially for women, who have relatively less muscle mass and more body fat, a specific
method to improve CVD risk factors and decrease weight is needed. One of the most effective
methods is regular exercise, which decreases body fat, lowers blood pressure, improves
hyperlipidemia, and lowers HDLC levels. Increases in metabolic equivalents and
cardiorespiratory fitness (CRF) decrease metabolic risk factors and effectively prevent
CVD<xref rid="r11" ref-type="bibr">11</xref>, <xref rid="r12" ref-type="bibr">12</xref><sup>)</sup>. Therefore, this research sought to solidify the exercise-related
physiologic evidence for regular aerobic exercise and the subsequent improvement in
cardiovascular risk factors in obese women and the apolipoprotein B/A-1ratio in obese
women.</p></sec><sec sec-type="methods" id="s2"><title>SUBJECTS AND METHODS</title><p>The study subjects included a total of 32 obese women between the ages of 40 and 49 without
medical problems. Subjects were randomly divided into two groups (n = 16 in each group): the
control group and the exercise group. They were selected after basic testing, which included
collection of information for age, exercise capacity, weight changes over the previous year,
smoking status, and currently used medications, and requirements included waist
circumference (WC) &#x02265;80&#x02005;cm and body mass index (BMI) &#x02265;25&#x02005;kg/m<sup>2</sup> along with
exercising less than twice per week. Before testing, the contents and objective of the
research were explained, and consent was obtained prior to subject participation. Kyungwoon
University approved this study, which complies with the ethical standards of the Declaration
of Helsinki. Physical characteristics of the subjects in each group are outlined in <xref rid="tbl_001" ref-type="table">Table 1</xref><table-wrap id="tbl_001" orientation="portrait" position="float"><label>Table 1.</label><caption><title>Physical characteristics of the participants in this experiment</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Age (years)</th><th align="center" rowspan="1" colspan="1">Height (cm)</th><th align="center" rowspan="1" colspan="1">Weight (kg)</th><th align="center" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</th><th align="center" rowspan="1" colspan="1">Body fat (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CON (N=16)</td><td align="center" rowspan="1" colspan="1">45.8&#x000b1;3.4</td><td align="center" rowspan="1" colspan="1">156.1&#x000b1;3.2</td><td align="center" rowspan="1" colspan="1">64.3&#x000b1;3.1</td><td align="center" rowspan="1" colspan="1">26.3&#x000b1;1.3</td><td align="center" rowspan="1" colspan="1">34.3&#x000b1;2.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Exercise (N=16)</td><td align="center" rowspan="1" colspan="1">47.0&#x000b1;2.9</td><td align="center" rowspan="1" colspan="1">158.1&#x000b1;4.2</td><td align="center" rowspan="1" colspan="1">65.1&#x000b1;3.1</td><td align="center" rowspan="1" colspan="1">26.0&#x000b1;1.2</td><td align="center" rowspan="1" colspan="1">32.8&#x000b1;3.2</td></tr></tbody></table><table-wrap-foot><p>Data are means &#x000b1; SD.</p></table-wrap-foot></table-wrap>.</p><p>The exercise program in this study consisted of walking at 50&#x02013;60% of the maximum volume of
minute oxygen consumption (VO<sub>2max</sub>) three times per week for 12 weeks. After a
VO<sub>2max</sub> treadmill test, oxygen consumption and heart beats per minute were
calculated, as were individual pulse rates/minute corresponding to 50&#x02013;60% of the
VO<sub>2max</sub> and individual logistic regression analysis were performed. To confirm
the target calorie expenditure obtained with a Polar Heart Monitor (Polar S610i, Polar
Electro, Kempele, Finland), the energy expenditure was calculated using the reached targeted
pulse designated during the walking exercise program. To standardize the expended energy per
session as 400&#x02005;kcal and 1,200&#x02005;kcal/week (3 times per week), the amount of time spent
performing exercise was adjusted to between 60 and 120 minutes depending on the individual&#x02019;s
ability. Physical measurements taken included height (cm), weight (kg), and the calculated
body mass index (BMI), which was calculated as BMI = weight (kg)/height (m<sup>2</sup>).
Percent body fat was assessed using the InBody 720 bioelectrical body composition analyzer
(Biospace, Seoul, Republic of Korea) following the procedures recommended by the American
College of Sports Medicine (ACSM)<xref rid="r11" ref-type="bibr">11</xref><sup>)</sup>.
Waist circumference was measured with a tape, while blood pressure was measured with an
automatic machine (Tensoval Comfort, Paul Hartmann AG, Heidenheim, Germany) and included
systolic (SBP) and diastolic (DBP) blood pressure measurements. Mean arterial pressure (MAP)
was calculated by using the following equation: MAP = DBP+((SBP&#x02212;DBP)/3). The
VO<sub>2max</sub> as an index of cardiorespiratory fitness (CRF), was measured on a motor
driven treadmill using the Bruce protocol, as described in the ACSM guidelines (2010)<xref rid="r11" ref-type="bibr">11</xref><sup>)</sup>. Oxygen consumption (VO<sub>2</sub>) was
measured using standard breath-by-breath techniques of pulmonary gas exchange variables
(Metabolic Gas Analyzer System; Quark b<sup>2</sup>, Cosmed, Italy), and exercise heart rate
was measured using 12-lead electrocardiography (Q-4500, Quinton Cardiology Systems, Bothell,
WA, USA). VO<sub>2max</sub> was considered the highest oxygen consumption attained at the
exhaustion moment.</p><p>Blood sample analyses were performed simultaneously under the same conditions before and
after the exercise program. The obtained blood samples were separated by centrifugation at
4&#x02005;&#x000b0;C, and TG (triglyceride; Vitros TRIG DTD, Johnson &#x00026; Johnson, NY, USA), and TC (total
cholesterol; Vitros CHOL DTD, Johnson &#x00026; Johnson, NY, USA) were analyzed on an slide
using a Vitros DT60II chemistry system (Johnson &#x00026; Johnson, NY, USA). With HDLC using
magnesium chloride and dextran sulfate, the cholesterol-containing apoB was precipitated,
and using the HDLC (HDL cholesterol; Vitros HDLC DTD, Johnson &#x00026; Johnson, NY, USA) slide,
analysis was performed with a Vitros DT60II chemistry system (Johnson &#x00026; Johnson, NY,
USA). The atherogenic index was calculated by using the following equation: AI = (TC &#x02212; HDLC)
/ HDLC<xref rid="r13" ref-type="bibr">13</xref><sup>)</sup>. ApoB and ApoA1 were analyzed by
using immunoturbidimetry (Hitachi Auto-Analyzer, Model 705, Hitachi, Tokyo, Japan).</p><p>All data are expressed as averages and standard deviations, and to observe the transitional
changes in the groups before and after exercise, two-way repeated measures ANOVA was
conducted. For comparison of changes in the average values of measured variables before and
after the 12 weeks of exercise training, the paired samples t-test was used. Moreover, the
change in values between before and after 12 weeks of exercise was extracted (&#x02206;score =
changed score between before and after 12 weeks of exercise). All statistical analyses were
performed by using SPSS for Window (version 18.0), and values of p=0.05 were considered
statistically significant.</p></sec><sec sec-type="results" id="s3"><title>RESULTS</title><p>A comparison of the changes in blood pressure and obesity index after 12 weeks of aerobic
exercise is shown in <xref rid="tbl_002" ref-type="table">Table 2</xref><table-wrap id="tbl_002" orientation="portrait" position="float"><label>Table 2.</label><caption><title>Changes in obesity indices and blood pressure with 12 weeks aerobic
exercise</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" rowspan="1" colspan="1">Measured variable</th><th align="center" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">Pre</th><th align="center" rowspan="1" colspan="1">Post</th><th align="center" rowspan="1" colspan="1">&#x02206;score</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Weight (kg)</td><td align="center" rowspan="1" colspan="1">CON</td><td align="left" rowspan="1" colspan="1">64.3&#x000b1;3.1</td><td align="center" rowspan="1" colspan="1">63.5&#x000b1;3.5</td><td align="center" rowspan="1" colspan="1">&#x02212;0.82&#x000b1;1.93</td></tr><tr><td align="center" rowspan="1" colspan="1">Exercise</td><td align="left" rowspan="1" colspan="1">65.1&#x000b1;3.1</td><td align="center" rowspan="1" colspan="1">62.0&#x000b1;3.0<sup>&#x02020;&#x02020;&#x02020;</sup></td><td align="center" rowspan="1" colspan="1">&#x02212;3.11&#x000b1;1.24***</td></tr><tr><td align="left" rowspan="2" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">CON</td><td align="center" rowspan="1" colspan="1">26.3&#x000b1;1.3</td><td align="center" rowspan="1" colspan="1">26.0&#x000b1;1.5</td><td align="center" rowspan="1" colspan="1">&#x02212;0.33&#x000b1;0.80</td></tr><tr><td align="center" rowspan="1" colspan="1">Exercise</td><td align="center" rowspan="1" colspan="1">26.0&#x000b1;1.2</td><td align="center" rowspan="1" colspan="1">24.8&#x000b1;1.3<sup>&#x02020;&#x02020;&#x02020;</sup></td><td align="center" rowspan="1" colspan="1">&#x02212;1.24&#x000b1;0.47***</td></tr><tr><td align="left" rowspan="2" colspan="1">WC (cm)</td><td align="center" rowspan="1" colspan="1">CON</td><td align="left" rowspan="1" colspan="1">89.5&#x000b1;5.2</td><td align="center" rowspan="1" colspan="1">89.2&#x000b1;4.9</td><td align="center" rowspan="1" colspan="1">&#x02212;0.36&#x000b1;0.83</td></tr><tr><td align="center" rowspan="1" colspan="1">Exercise</td><td align="center" rowspan="1" colspan="1">88.3&#x000b1;4.6</td><td align="center" rowspan="1" colspan="1">86.7&#x000b1;4.5</td><td align="center" rowspan="1" colspan="1">&#x02212;1.58&#x000b1;2.47*</td></tr><tr><td align="left" rowspan="2" colspan="1">Body fat (%)</td><td align="center" rowspan="1" colspan="1">CON</td><td align="center" rowspan="1" colspan="1">34.3&#x000b1;2.7</td><td align="center" rowspan="1" colspan="1">33.4&#x000b1;3.1</td><td align="center" rowspan="1" colspan="1">&#x02212;0.87&#x000b1;1.54</td></tr><tr><td align="center" rowspan="1" colspan="1">Exercise</td><td align="center" rowspan="1" colspan="1">32.8&#x000b1;3.2</td><td align="center" rowspan="1" colspan="1">30.6&#x000b1;3.5<sup>&#x02020;</sup></td><td align="center" rowspan="1" colspan="1">&#x02212;2.18&#x000b1;1.96***</td></tr><tr><td align="left" rowspan="2" colspan="1">SBP (mmHg)</td><td align="center" rowspan="1" colspan="1">CON</td><td align="center" rowspan="1" colspan="1">124.5&#x000b1;12.3</td><td align="center" rowspan="1" colspan="1">123.9&#x000b1;8.6</td><td align="center" rowspan="1" colspan="1">&#x02212;0.56&#x000b1;7.99</td></tr><tr><td align="center" rowspan="1" colspan="1">Exercise</td><td align="center" rowspan="1" colspan="1">121.9&#x000b1;13.6</td><td align="center" rowspan="1" colspan="1">117.0&#x000b1;9.7</td><td align="center" rowspan="1" colspan="1">&#x02212;4.84&#x000b1;10.23</td></tr><tr><td align="left" rowspan="2" colspan="1">DBP (mmHg)</td><td align="center" rowspan="1" colspan="1">CON</td><td align="center" rowspan="1" colspan="1">80.8&#x000b1;10.3</td><td align="center" rowspan="1" colspan="1">79.2&#x000b1;10.7</td><td align="center" rowspan="1" colspan="1">&#x02212;1.56&#x000b1;9.42</td></tr><tr><td align="center" rowspan="1" colspan="1">Exercise</td><td align="left" rowspan="1" colspan="1">77.2&#x000b1;9.7</td><td align="center" rowspan="1" colspan="1">80.4&#x000b1;7.8</td><td align="center" rowspan="1" colspan="1">3.18&#x000b1;6.45</td></tr><tr><td align="left" rowspan="2" colspan="1">MAP (mmHg)</td><td align="center" rowspan="1" colspan="1">CON</td><td align="center" rowspan="1" colspan="1">95.3&#x000b1;10.3</td><td align="center" rowspan="1" colspan="1">94.1&#x000b1;9.1</td><td align="center" rowspan="1" colspan="1">&#x02212;1.22&#x000b1;7.11</td></tr><tr><td align="center" rowspan="1" colspan="1">Exercise</td><td align="center" rowspan="1" colspan="1">92.1&#x000b1;10.5</td><td align="center" rowspan="1" colspan="1">92.6&#x000b1;7.8</td><td align="center" rowspan="1" colspan="1">0.51&#x000b1;7.37</td></tr></tbody></table><table-wrap-foot><p>Data are means. &#x02206;score = change in the score from before the exercise program to 12
weeks * p value of paired t-test (*p&#x0003c;0.05; **p&#x0003c;0.01; ***p&#x0003c;0.001).
<sup>&#x02020;</sup> p value of two-way ANOVA test (group&#x000d7;time; <sup>&#x02020;</sup>p&#x0003c;0.05;
<sup>&#x02020;&#x02020;</sup>p&#x0003c;0.01; <sup>&#x02020;&#x02020;&#x02020;</sup>p&#x0003c;0.001). BMI, body mass index; WC, waist
circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean
arterial pressure</p></table-wrap-foot></table-wrap>. Weight (p&#x0003c;0.001), BMI (p&#x0003c;0.001), and percent body fat (p&#x0003c;0.05)
demonstrated statistically significant interactions (p&#x0003c;0.05). WC decreased statistically
significantly after 12 weeks of aerobic exercise (p&#x0003c;0.05). However, blood pressure (SBP,
DBP, MAP) did not demonstrate significant effects.</p><p>The cardiovascular fitness and cardiovascular risk factor comparison results are shown in
<xref rid="tbl_003" ref-type="table">Table 3</xref><table-wrap id="tbl_003" orientation="portrait" position="float"><label>Table 3.</label><caption><title>Changes in the cardiorespiratory fitness and apoB/apoA1 ratio with 12 weeks
aerobic exercise</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" rowspan="1" colspan="1">Measured variable</th><th align="center" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">Pre</th><th align="center" rowspan="1" colspan="1">Post</th><th align="center" rowspan="1" colspan="1">&#x02206;score</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">VO<sub>2max</sub>(mL/kg/min)</td><td align="center" rowspan="1" colspan="1">CON</td><td align="center" rowspan="1" colspan="1">28.7&#x000b1;2.8</td><td align="center" rowspan="1" colspan="1">29.9&#x000b1;3.8</td><td align="center" rowspan="1" colspan="1">1.20&#x000b1;2.48</td></tr><tr><td align="center" rowspan="1" colspan="1">Exercise</td><td align="center" rowspan="1" colspan="1">30.9&#x000b1;3.4</td><td align="center" rowspan="1" colspan="1">34.3&#x000b1;3.2<sup>&#x02020;</sup></td><td align="center" rowspan="1" colspan="1">3.32&#x000b1;2.72***</td></tr><tr><td align="left" rowspan="2" colspan="1">TG (mg/dL)</td><td align="center" rowspan="1" colspan="1">CON</td><td align="center" rowspan="1" colspan="1">116.0&#x000b1;49.6</td><td align="center" rowspan="1" colspan="1">121.5&#x000b1;60.3</td><td align="center" rowspan="1" colspan="1">5.50&#x000b1;52.19</td></tr><tr><td align="center" rowspan="1" colspan="1">Exercise</td><td align="center" rowspan="1" colspan="1">120.4&#x000b1;94.1</td><td align="center" rowspan="1" colspan="1">93.0&#x000b1;41.8</td><td align="center" rowspan="1" colspan="1">&#x02212;27.37&#x000b1;71.53</td></tr><tr><td align="left" rowspan="2" colspan="1">TC (mg/dL)</td><td align="center" rowspan="1" colspan="1">CON</td><td align="center" rowspan="1" colspan="1">210.0&#x000b1;38.2</td><td align="center" rowspan="1" colspan="1">202.9&#x000b1;35.0</td><td align="center" rowspan="1" colspan="1">&#x02212;7.12&#x000b1;26.30</td></tr><tr><td align="center" rowspan="1" colspan="1">Exercise</td><td align="center" rowspan="1" colspan="1">201.6&#x000b1;44.1</td><td align="center" rowspan="1" colspan="1">185.1&#x000b1;41.4</td><td align="center" rowspan="1" colspan="1">&#x02212;16.43&#x000b1;23.46*</td></tr><tr><td align="left" rowspan="2" colspan="1">HDLC (mg/dL)</td><td align="center" rowspan="1" colspan="1">CON</td><td align="center" rowspan="1" colspan="1">46.6&#x000b1;15.4</td><td align="center" rowspan="1" colspan="1">44.3&#x000b1;10.2</td><td align="center" rowspan="1" colspan="1">&#x02212;2.31&#x000b1;11.09</td></tr><tr><td align="center" rowspan="1" colspan="1">Exercise</td><td align="left" rowspan="1" colspan="1">45.0&#x000b1;13.1</td><td align="center" rowspan="1" colspan="1">51.1&#x000b1;15.0<sup>&#x02020;</sup></td><td align="center" rowspan="1" colspan="1">6.15&#x000b1;8.53*</td></tr><tr><td align="left" rowspan="2" colspan="1">Atherogenic index</td><td align="center" rowspan="1" colspan="1">CON</td><td align="center" rowspan="1" colspan="1">4.01&#x000b1;2.13</td><td align="center" rowspan="1" colspan="1">3.80&#x000b1;1.41</td><td align="center" rowspan="1" colspan="1">&#x02212;0.20&#x000b1;1.54</td></tr><tr><td align="center" rowspan="1" colspan="1">Exercise</td><td align="center" rowspan="1" colspan="1">3.87&#x000b1;1.94</td><td align="center" rowspan="1" colspan="1">2.98&#x000b1;1.58</td><td align="center" rowspan="1" colspan="1">&#x02212;0.89&#x000b1;1.17*</td></tr><tr><td align="left" rowspan="2" colspan="1">Apolipoprotein B</td><td align="center" rowspan="1" colspan="1">CON</td><td align="center" rowspan="1" colspan="1">79.2&#x000b1;17.8</td><td align="center" rowspan="1" colspan="1">81.1&#x000b1;18.9</td><td align="center" rowspan="1" colspan="1">1.86&#x000b1;10.59</td></tr><tr><td align="center" rowspan="1" colspan="1">Exercise</td><td align="center" rowspan="1" colspan="1">84.5&#x000b1;17.1</td><td align="center" rowspan="1" colspan="1">73.2&#x000b1;15.9<sup>&#x02020;&#x02020;&#x02020;</sup></td><td align="center" rowspan="1" colspan="1">&#x02212;11.35&#x000b1;8.44***</td></tr><tr><td align="left" rowspan="2" colspan="1">Apolipoprotein A-1</td><td align="center" rowspan="1" colspan="1">CON</td><td align="center" rowspan="1" colspan="1">152.3&#x000b1;26.5</td><td align="center" rowspan="1" colspan="1">153.3&#x000b1;28.8</td><td align="center" rowspan="1" colspan="1">0.96&#x000b1;23.73</td></tr><tr><td align="center" rowspan="1" colspan="1">Exercise</td><td align="center" rowspan="1" colspan="1">151.0&#x000b1;28.9</td><td align="center" rowspan="1" colspan="1">156.2&#x000b1;32.6</td><td align="center" rowspan="1" colspan="1">5.18&#x000b1;14.60</td></tr><tr><td align="left" rowspan="2" colspan="1">ApoB/ApoA-1 ratio</td><td align="center" rowspan="1" colspan="1">CON</td><td align="center" rowspan="1" colspan="1">0.53&#x000b1;0.16</td><td align="center" rowspan="1" colspan="1">0.54&#x000b1;0.16</td><td align="center" rowspan="1" colspan="1">0.01&#x000b1;0.12</td></tr><tr><td align="center" rowspan="1" colspan="1">Exercise</td><td align="center" rowspan="1" colspan="1">0.58&#x000b1;0.17</td><td align="center" rowspan="1" colspan="1">0.49&#x000b1;0.19<sup>&#x02020;</sup></td><td align="center" rowspan="1" colspan="1">&#x02212;0.08&#x000b1;0.09**</td></tr></tbody></table><table-wrap-foot><p>Data are means. &#x02206;score = change in the score from before the exercise program to 12
weeks, * p value of paired t-test (*p&#x0003c;0.05; **p&#x0003c;0.01; ***p&#x0003c;0.001).
<sup>&#x02020;</sup> p value of two-way ANOVA test (group&#x000d7;time; <sup>&#x02020;</sup>p&#x0003c;0.05;
<sup>&#x02020;&#x02020;</sup>p&#x0003c;0.01; <sup>&#x02020;&#x02020;&#x02020;</sup>p&#x0003c;0.001). TG, triglycerides; TC, total
cholesterol; HDLC, high density lipoprotein cholesterol</p></table-wrap-foot></table-wrap>. A marker of cardiovascular fitness, VO<sub>2max</sub> (p&#x0003c;0.05),
demonstrated statistically significant interactions. HDLC (p&#x0003c;0.05), apoB (p&#x0003c;0.001),
and the apoB/apoA1 ratio (p&#x0003c;0.05) demonstrated statistically significant interactions. TC
(p&#x0003c;0.05) and AI (p&#x0003c;0.05) demonstrated statistically significant decreases after 12
weeks of exercise. However, TG and apoA1 did not demonstrate statistically significant
differences.</p></sec><sec sec-type="discussion" id="s4"><title>DISCUSSION</title><p>The ACSM<xref rid="r11" ref-type="bibr">11</xref><sup>)</sup> recommends 45 to 60 minutes
of exercise daily, which consumes 300 to 400&#x02005;kcal, to improve obesity and reduce weight.
Fogelholm<xref rid="r14" ref-type="bibr">14</xref><sup>)</sup> also reported that to
effectively decrease weight, a minimum of 35 to 45 minutes of exercise per day for a total
of 250 to 300 minutes per week are required. In this study&#x02019;s results, 12 weeks of aerobic
exercise in obese women significantly decreased obesity indices such as weight, BMI, and
percent body fat. It is thought that it was appropriate to set the exercise volume at a
level that does not cause fatigue in the weight control program for obese women. However,
there were no changes in blood pressure (SBP, DBP, MAP). This is thought to be due to the
fact that the subjects had normal blood pressures.</p><p>Generally speaking, indices evaluating cardiorespiratory fitness (CRF) include
VO<sub>2max</sub>, which represents the oxygen-carrying capacity of the active muscles
during exercise. VO<sub>2max</sub> decreases by 1% per year (setting 25&#x02005;years as the
standard), and the decrease in VO<sub>2max</sub> displays an intimate relationship with
chronic diseases and CVD<xref rid="r15" ref-type="bibr">15</xref><sup>)</sup>. Regular
aerobic exercise is a good method for enhancing VO<sub>2max</sub>, enhancing cardiovascular
function, and effectively preventing and delaying CVD<xref rid="r11" ref-type="bibr">11</xref><sup>)</sup>. This study&#x02019;s results show a significant increase in
VO<sub>2max</sub> after 12 weeks of aerobic exercise. In reality, Katzmarzyk et al.<xref rid="r16" ref-type="bibr">16</xref><sup>)</sup> reported that aerobic exercise resulted in
an increase in CRF in 19,173 obese subjects. Moreover, LaMonte et al.<xref rid="r17" ref-type="bibr">17</xref><sup>)</sup> reported that VO<sub>2max</sub> is an independent and
strong predictor of CVD and a metabolic risk factor in both women and men.</p><p>HDLC plays a critical role in maintaining homeostasis of the TC quantity. This role of HDLC
is due to RCT, through which HDLC may block the formation of atherosclerosis<xref rid="r18" ref-type="bibr">18</xref><sup>)</sup>. RCT eliminates surplus cholesterol
residing in the macrophages of the arterial walls, transports it to the liver, and exports
it in vitro, basically eliminating the production of atherosclerotic plaque<xref rid="r19" ref-type="bibr">19</xref><sup>)</sup>. RCT is the only mechanism that can
eliminate surplus cholesterol within the body, and is therefore a critical factor in
maintaining appropriate concentrations and functions of HDLC in prevention of CVD.
Specifically, low HDLC concentrations are known to independently raise the frequency of CVD
along with other risk factors<xref rid="r20" ref-type="bibr">20</xref><sup>)</sup>. Based on
these results, HDLC demonstrated significant interactions. Jenkins et al.<xref rid="r21" ref-type="bibr">21</xref><sup>)</sup> reported that aerobic exercise effectively
increased HDLC concentrations, while Katzmarzyk et al.<xref rid="r16" ref-type="bibr">16</xref><sup>)</sup> reported that HDLC concentrations increased in obese patients with
metabolic syndrome, which was in line with our research. TC and AI decreased significantly
after exercise training in the present study. Because the equation AI = (TC&#x02212;HDLC/HDLC) was
used, increases in HDLC due to exercise and decreases in TC yielded a decrease in AI.
Normally, an AI value &#x0003c; 3 is noted as normal<xref rid="r13" ref-type="bibr">13</xref><sup>)</sup>; after exercise in the present study, the values normalized, which
indicates that the exercise training was effective.</p><p>ApoA1 is one of the most basic units in the formation of HDLC and is a critical component
of HDLC. ApoA1 is synthesized in the liver and gastrointestinal tract and secreted into the
plasma, and through the action of the cell membrane protein of the peripheral tissues, known
as ATP-binding cassette transporter A1 (ABCA1), cholesterol within cells is transported to
apoA1 and forms HDLC<xref rid="r22" ref-type="bibr">22</xref><sup>)</sup>. It is known that
as the synthesis of apoA1 is increased by long-term exercise, catabolism decreases<xref rid="r23" ref-type="bibr">23</xref><sup>)</sup>. However, in this research, there were no
significant increases in apoA1. Such results are thought to be due to the exercise volume or
length not being sufficient to change the blood concentration of apoA1. Additionally, those
kinetics of apoA1 may be attributable to the fact that the subjects were obese. In obese
individuals, as compared with normal individuals, hypercatabolism occurs relative to apoA1
synthesis speed<xref rid="r24" ref-type="bibr">24</xref><sup>)</sup>. In fact, the changes
in apoA1 in this study are thought to be related to the apoA1 synthesis speed. However, it
is difficult to arrive at conclusions based on insufficient data.</p><p>ApoB is a critical protein component of LDLC that increases the absorption of cellular
cholesterol by combining LDL particles with the LDL receptor. Such apoB is intimately
associated with blood concentrations of LDLC and CVD, and apoB plays an important role in
improving blood lipid concentrations<xref rid="r9" ref-type="bibr">9</xref><sup>)</sup>.
ApoB and the apoB/apoA1 ratio are clinical indices for metabolic risk factors, specifically
predicting CVD risk and lowering cholesterol, which are useful markers for treatment
progress. Recently, regular exercise has been shown to decrease the apoB level and
apoB/apoA1 ratio, directly influencing CVD prevention<xref rid="r25" ref-type="bibr">25</xref><sup>)</sup>. Based on this study&#x02019;s results, apoB and the apoB/apoA1 ratio
demonstrated significant interactions. Holme et al.<xref rid="r25" ref-type="bibr">25</xref><sup>)</sup> reported that in a study with overweight males, regular aerobic
exercise decreased apoB levels and the apoB/apoA1 ratio, and Ben Ounis et al.<xref rid="r26" ref-type="bibr">26</xref><sup>)</sup> reported the same findings. Also, Crouse
et al.<xref rid="r27" ref-type="bibr">27</xref><sup>)</sup>, in a study involving adults
with hypercholesterolemia, reported that aerobic exercise decreased apoB, and Janssen et
al.<xref rid="r28" ref-type="bibr">28</xref><sup>)</sup> showed that aerobic exercise and
diet control in obese women decreased the apoB/apoA1 ratio. However, Henderson et al.<xref rid="r29" ref-type="bibr">29</xref><sup>)</sup> reported that solitary exercise did not
impact lipoproteins such as apoB and apoA1, so long-term aerobic exercise is thought to be
relatively effective. Based on this study&#x02019;s results, regular aerobic exercise significantly
improved the obesity index, CRF, blood HDLC, and apoB/apoA1 ratio in obese women. Such
results suggest that regular exercise can effectively improve the obesity index along with
cardiovascular risk factors. However, TG and apoA1 levels did not change significantly, so
exercise intensity, frequency, and duration may need to be considered and increased.</p></sec></body><back><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><mixed-citation publication-type="other">World Health Organization:
Obesity and overweight. Global strategy on diet, physical activity and health,
<year>2011</year>.</mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group><name><surname>Wooten</surname><given-names>JS</given-names></name><name><surname>Biggerstaff</surname><given-names>KD</given-names></name><name><surname>Anderson</surname><given-names>C</given-names></name></person-group>: <article-title>Response of lipid, lipoprotein-cholesterol, and
electrophoretic characteristics of lipoproteins following a single bout of aerobic
exercise in women</article-title>. <source>Eur J Appl Physiol</source>,
<year>2008</year>, <volume>104</volume>: <fpage>19</fpage>&#x02013;<lpage>27</lpage>.
<pub-id pub-id-type="pmid">18509669</pub-id></mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group><name><surname>Walldius</surname><given-names>G</given-names></name><name><surname>Jungner</surname><given-names>I</given-names></name></person-group>: <article-title>Apolipoprotein B and apolipoprotein A-I: risk indicators
of coronary heart disease and targets for lipid-modifying therapy</article-title>.
<source>J Intern Med</source>, <year>2004</year>, <volume>255</volume>:
<fpage>188</fpage>&#x02013;<lpage>205</lpage>. <pub-id pub-id-type="pmid">14746556</pub-id></mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group><name><surname>Durstine</surname><given-names>JL</given-names></name><name><surname>Grandjean</surname><given-names>PW</given-names></name><name><surname>Cox</surname><given-names>CA</given-names></name><etal>et al.</etal></person-group>: <article-title>Lipids, lipoproteins, and exercise</article-title>.
<source>J Cardiopulm Rehabil</source>, <year>2002</year>, <volume>22</volume>:
<fpage>385</fpage>&#x02013;<lpage>398</lpage>. <pub-id pub-id-type="pmid">12464825</pub-id></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group><name><surname>Chapman</surname><given-names>MJ</given-names></name><name><surname>Assmann</surname><given-names>G</given-names></name><name><surname>Fruchart</surname><given-names>JC</given-names></name><etal>et al.</etal></person-group>European Consensus Panel on HDL-C: <article-title>raising high-density
lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic
acid&#x02014;a position paper developed by the European Consensus Panel on
HDL-C</article-title>. <source>Curr Med Res Opin</source>, <year>2004</year>,
<volume>20</volume>: <fpage>1253</fpage>&#x02013;<lpage>1268</lpage>. <pub-id pub-id-type="pmid">15324528</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group><name><surname>Tsompanidi</surname><given-names>EM</given-names></name><name><surname>Brinkmeier</surname><given-names>MS</given-names></name><name><surname>Fotiadou</surname><given-names>EH</given-names></name><etal>et al.</etal></person-group>: <article-title>HDL biogenesis and functions: role of HDL quality and
quantity in atherosclerosis</article-title>. <source>Atherosclerosis</source>,
<year>2010</year>, <volume>208</volume>: <fpage>3</fpage>&#x02013;<lpage>9</lpage>.
<pub-id pub-id-type="pmid">19595353</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group><name><surname>Sniderman</surname><given-names>AD</given-names></name><name><surname>Faraj</surname><given-names>M</given-names></name></person-group>: <article-title>Apolipoprotein B, apolipoprotein A-I, insulin resistance
and the metabolic syndrome</article-title>. <source>Curr Opin Lipidol</source>,
<year>2007</year>, <volume>18</volume>: <fpage>633</fpage>&#x02013;<lpage>637</lpage>.
<pub-id pub-id-type="pmid">17993808</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group><name><surname>Wallenfeldt</surname><given-names>K</given-names></name><name><surname>Bokemark</surname><given-names>L</given-names></name><name><surname>Wikstrand</surname><given-names>J</given-names></name><etal>et al.</etal></person-group>: <article-title>Apolipoprotein B/apolipoprotein A-I in relation to the
metabolic syndrome and change in carotid artery intima-media thickness during 3 years in
middle-aged men</article-title>. <source>Stroke</source>, <year>2004</year>,
<volume>35</volume>: <fpage>2248</fpage>&#x02013;<lpage>2252</lpage>. <pub-id pub-id-type="pmid">15345795</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group><name><surname>Vaverkova</surname><given-names>H</given-names></name><name><surname>Karasek</surname><given-names>D</given-names></name><name><surname>Novotny</surname><given-names>D</given-names></name><etal>et al.</etal></person-group>: <article-title>Apolipoprotein B versus LDL-cholesterol: association with
other risk factors for atherosclerosis</article-title>. <source>Clin Biochem</source>,
<year>2009</year>, <volume>42</volume>: <fpage>1246</fpage>&#x02013;<lpage>1251</lpage>.
<pub-id pub-id-type="pmid">19450572</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group><name><surname>Sierra-Johnson</surname><given-names>J</given-names></name><name><surname>Somers</surname><given-names>VK</given-names></name><name><surname>Kuniyoshi</surname><given-names>FH</given-names></name><etal>et al.</etal></person-group>: <article-title>Comparison of apolipoprotein-B/apolipoprotein-AI in
subjects with versus without the metabolic syndrome</article-title>. <source>Am J
Cardiol</source>, <year>2006</year>, <volume>98</volume>:
<fpage>1369</fpage>&#x02013;<lpage>1373</lpage>. <pub-id pub-id-type="pmid">17134631</pub-id></mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="book">American College of Sports
Medicine: ACSM&#x02019;s Guidelines for exercise testing and prescription, 8th ed. Philadelpia:
Lippincott Williams and Wilkins, <year>2010</year>.</mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group><name><surname>Kim</surname><given-names>DY</given-names></name><name><surname>Jung</surname><given-names>SY</given-names></name><name><surname>Seo</surname><given-names>BD</given-names></name></person-group>: <article-title>Effect of exercise intervention on changes in free Fatty
Acid levels and metabolic risk factors in stroke patients</article-title>. <source>J
Phys Ther Sci</source>, <year>2014</year>, <volume>26</volume>:
<fpage>275</fpage>&#x02013;<lpage>279</lpage>. <pub-id pub-id-type="pmid">24648648</pub-id></mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group><name><surname>Haglund</surname><given-names>O</given-names></name><name><surname>Luostarinen</surname><given-names>R</given-names></name><name><surname>Wallin</surname><given-names>R</given-names></name><etal>et al.</etal></person-group>: <article-title>The effects of fish oil on triglycerides, cholesterol,
fibrinogen and malondialdehyde in humans supplemented with vitamin E</article-title>.
<source>J Nutr</source>, <year>1991</year>, <volume>121</volume>:
<fpage>165</fpage>&#x02013;<lpage>169</lpage>. <pub-id pub-id-type="pmid">1995786</pub-id></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group><name><surname>Fogelholm</surname><given-names>M</given-names></name></person-group>: <article-title>Walking for the management of obesity</article-title>.
<source>Dis Manag Health Outcomes</source>, <year>2005</year>, <volume>13</volume>:
<fpage>9</fpage>&#x02013;<lpage>18</lpage>. </mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group><name><surname>Buskirk</surname><given-names>ER</given-names></name><name><surname>Hodgson</surname><given-names>JL</given-names></name></person-group>: <article-title>Age and aerobic power: the rate of change in men and
women</article-title>. <source>Fed Proc</source>, <year>1987</year>,
<volume>46</volume>: <fpage>1824</fpage>&#x02013;<lpage>1829</lpage>. <pub-id pub-id-type="pmid">3493922</pub-id></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group><name><surname>Katzmarzyk</surname><given-names>PT</given-names></name><name><surname>Church</surname><given-names>TS</given-names></name><name><surname>Janssen</surname><given-names>I</given-names></name><etal>et al.</etal></person-group>: <article-title>Metabolic syndrome, obesity, and mortality: impact of
cardiorespiratory fitness</article-title>. <source>Diabetes Care</source>,
<year>2005</year>, <volume>28</volume>: <fpage>391</fpage>&#x02013;<lpage>397</lpage>.
<pub-id pub-id-type="pmid">15677798</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group><name><surname>LaMonte</surname><given-names>MJ</given-names></name><name><surname>Barlow</surname><given-names>CE</given-names></name><name><surname>Jurca</surname><given-names>R</given-names></name><etal>et al.</etal></person-group>: <article-title>Cardiorespiratory fitness is inversely associated with the
incidence of metabolic syndrome: a prospective study of men and women</article-title>.
<source>Circulation</source>, <year>2005</year>, <volume>112</volume>:
<fpage>505</fpage>&#x02013;<lpage>512</lpage>. <pub-id pub-id-type="pmid">16009797</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group><name><surname>Shah</surname><given-names>PK</given-names></name><name><surname>Kaul</surname><given-names>S</given-names></name><name><surname>Nilsson</surname><given-names>J</given-names></name><etal>et al.</etal></person-group>: <article-title>Exploiting the vascular protective effects of high-density
lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part
I</article-title>. <source>Circulation</source>, <year>2001</year>,
<volume>104</volume>: <fpage>2376</fpage>&#x02013;<lpage>2383</lpage>. <pub-id pub-id-type="pmid">11696481</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group><name><surname>Fielding</surname><given-names>CJ</given-names></name><name><surname>Fielding</surname><given-names>PE</given-names></name></person-group>: <article-title>Molecular physiology of reverse cholesterol
transport</article-title>. <source>J Lipid Res</source>, <year>1995</year>,
<volume>36</volume>: <fpage>211</fpage>&#x02013;<lpage>228</lpage>. <pub-id pub-id-type="pmid">7751809</pub-id></mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group><name><surname>Singh</surname><given-names>IM</given-names></name><name><surname>Shishehbor</surname><given-names>MH</given-names></name><name><surname>Ansell</surname><given-names>BJ</given-names></name></person-group>: <article-title>High-density lipoprotein as a therapeutic target: a
systematic review</article-title>. <source>JAMA</source>, <year>2007</year>,
<volume>298</volume>: <fpage>786</fpage>&#x02013;<lpage>798</lpage>. <pub-id pub-id-type="pmid">17699012</pub-id></mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group><name><surname>Jenkins</surname><given-names>NT</given-names></name><name><surname>McKenzie</surname><given-names>JA</given-names></name><name><surname>Damcott</surname><given-names>CM</given-names></name><etal>et al.</etal></person-group>: <article-title>Endurance exercise training effects on body fatness,
VO<sub>2max</sub>, HDL-C subfractions, and glucose tolerance are influenced by a PLIN
haplotype in older Caucasians</article-title>. <source>J Appl Physiol 1985</source>,
<year>2010</year>, <volume>108</volume>: <fpage>498</fpage>&#x02013;<lpage>506</lpage>.
<pub-id pub-id-type="pmid">19850727</pub-id></mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group><name><surname>Attie</surname><given-names>AD</given-names></name><name><surname>Kastelein</surname><given-names>JP</given-names></name><name><surname>Hayden</surname><given-names>MR</given-names></name></person-group>: <article-title>Pivotal role of ABCA1 in reverse cholesterol transport
influencing HDL levels and susceptibility to atherosclerosis</article-title>. <source>J
Lipid Res</source>, <year>2001</year>, <volume>42</volume>:
<fpage>1717</fpage>&#x02013;<lpage>1726</lpage>. <pub-id pub-id-type="pmid">11714841</pub-id></mixed-citation></ref><ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group><name><surname>Olchawa</surname><given-names>B</given-names></name><name><surname>Kingwell</surname><given-names>BA</given-names></name><name><surname>Hoang</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>: <article-title>Physical fitness and reverse cholesterol
transport</article-title>. <source>Arterioscler Thromb Vasc Biol</source>,
<year>2004</year>, <volume>24</volume>: <fpage>1087</fpage>&#x02013;<lpage>1091</lpage>.
<pub-id pub-id-type="pmid">15072992</pub-id></mixed-citation></ref><ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group><name><surname>Ooi</surname><given-names>EM</given-names></name><name><surname>Watts</surname><given-names>GF</given-names></name><name><surname>Farvid</surname><given-names>MS</given-names></name><etal>et al.</etal></person-group>: <article-title>High-density lipoprotein apolipoprotein A-I kinetics in
obesity</article-title>. <source>Obes Res</source>, <year>2005</year>,
<volume>13</volume>: <fpage>1008</fpage>&#x02013;<lpage>1016</lpage>. <pub-id pub-id-type="pmid">15976143</pub-id></mixed-citation></ref><ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group><name><surname>Holme</surname><given-names>I</given-names></name><name><surname>H&#x000f8;stmark</surname><given-names>AT</given-names></name><name><surname>Anderssen</surname><given-names>SA</given-names></name></person-group>: <article-title>ApoB but not LDL-cholesterol is reduced by exercise
training in overweight healthy men. Results from the 1-year randomized Oslo Diet and
Exercise Study</article-title>. <source>J Intern Med</source>, <year>2007</year>,
<volume>262</volume>: <fpage>235</fpage>&#x02013;<lpage>243</lpage>. <pub-id pub-id-type="pmid">17645591</pub-id></mixed-citation></ref><ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group><name><surname>Ben Ounis</surname><given-names>O</given-names></name><name><surname>Elloumi</surname><given-names>M</given-names></name><name><surname>Makni</surname><given-names>E</given-names></name><etal>et al.</etal></person-group>: <article-title>Exercise improves the ApoB/ApoA-I ratio, a marker of the
metabolic syndrome in obese children</article-title>. <source>Acta Paediatr</source>,
<year>2010</year>, <volume>99</volume>: <fpage>1679</fpage>&#x02013;<lpage>1685</lpage>.
<pub-id pub-id-type="pmid">20594189</pub-id></mixed-citation></ref><ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group><name><surname>Crouse</surname><given-names>SF</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>BC</given-names></name><name><surname>Grandjean</surname><given-names>PW</given-names></name><etal>et al.</etal></person-group>: <article-title>Effects of training and a single session of exercise on
lipids and apolipoproteins in hypercholesterolemic men</article-title>. <source>J Appl
Physiol 1985</source>, <year>1997</year>, <volume>83</volume>:
<fpage>2019</fpage>&#x02013;<lpage>2028</lpage>. <pub-id pub-id-type="pmid">9390976</pub-id></mixed-citation></ref><ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group><name><surname>Janssen</surname><given-names>I</given-names></name><name><surname>Fortier</surname><given-names>A</given-names></name><name><surname>Hudson</surname><given-names>R</given-names></name><etal>et al.</etal></person-group>: <article-title>Effects of an energy-restrictive diet with or without
exercise on abdominal fat, intermuscular fat, and metabolic risk factors in obese
women</article-title>. <source>Diabetes Care</source>, <year>2002</year>,
<volume>25</volume>: <fpage>431</fpage>&#x02013;<lpage>438</lpage>. <pub-id pub-id-type="pmid">11874926</pub-id></mixed-citation></ref><ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group><name><surname>Henderson</surname><given-names>GC</given-names></name><name><surname>Krauss</surname><given-names>RM</given-names></name><name><surname>Fattor</surname><given-names>JA</given-names></name><etal>et al.</etal></person-group>: <article-title>Plasma triglyceride concentrations are rapidly reduced
following individual bouts of endurance exercise in women</article-title>. <source>Eur J
Appl Physiol</source>, <year>2010</year>, <volume>109</volume>:
<fpage>721</fpage>&#x02013;<lpage>730</lpage>. <pub-id pub-id-type="pmid">20217117</pub-id></mixed-citation></ref></ref-list></back></article>
